HTDS hep A vaccine sales growing in India

Chinese firm Hard To Treat Diseases (HTDS) says that its China-based operating subsidiary, Mellow Hope, has surpassed sales of 200,000 units  of hepatitis A vaccine in India.

This vaccine, BIOVAC-A, was first launched in India in December 2005.  Terry Yuan, chief executive, said: "because our product is single-dose  vaccine, so our price is almost the half of other multinational  competitors' price. Our sales volume keeps growing continuously. To well  promote our AV and convince the local people that our product is equal  or better to our multinational competitors, we had conducted a  multicentric clinical trial in 2007. The results proved that our product  offers great safety and efficacy. Subsequently, this trial report was  published in the International Journal. As a company, we hold two  seminars every year, one in India and one in China."